Literature DB >> 24496054

Commercializing diarrhea vaccines for travelers.

Rosa López-Gigosos1, Marina Segura-Moreno2, Rosa Díez-Díaz2, Elena Plaza2, Alberto Mariscal3.   

Abstract

Continued growth in international travel and forecasts for a great increase in the number of people who travel from industrialized to emerging and developing countries make it necessary to develop and improve the capacity to provide health protection to travelers. Measures available to prevent some diseases include a currently limited number of marketed vaccines which represent extremely useful tools to protect travelers. Travelers very often experience diarrheal and gastrointestinal diseases for which some vaccines are available. Use of these vaccines should be evaluated based on traveler and travel destination and characteristics. Vaccines available include those against cholera, typhoid fever, hepatitis A, hepatitis E (only available in China), and rotavirus. The aim of this review is to provide an updated summary about each of the abovementioned vaccines that may be useful for making decisions regarding their use and assessing their indications in recommendations for travelers.

Entities:  

Keywords:  cholera; commercializing vaccines; hepatitis A; hepatitis E; rotavirus; traveler’s diarrhea; typhoid fever; vaccines

Mesh:

Substances:

Year:  2014        PMID: 24496054      PMCID: PMC5396228          DOI: 10.4161/hv.27737

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  45 in total

1.  Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine.

Authors:  M M Levine; C Ferreccio; P Abrego; O S Martin; E Ortiz; S Cryz
Journal:  Vaccine       Date:  1999-10-01       Impact factor: 3.641

Review 2.  Economic aspects of travelers' diarrhea.

Authors:  Mathyas Wang; Thomas D Szucs; Robert Steffen
Journal:  J Travel Med       Date:  2008 Mar-Apr       Impact factor: 8.490

Review 3.  Emergence of Salmonella paratyphi A as a major cause of enteric fever: need for early detection, preventive measures, and effective vaccines.

Authors:  Monthida Fangtham; Henry Wilde
Journal:  J Travel Med       Date:  2008 Sep-Oct       Impact factor: 8.490

4.  Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines.

Authors:  C O Tacket; C Ferreccio; J B Robbins; C M Tsai; D Schulz; M Cadoz; A Goudeau; M M Levine
Journal:  J Infect Dis       Date:  1986-08       Impact factor: 5.226

5.  Efficacy of atovaquone/proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccines.

Authors:  Jean-François Faucher; Ronnie Binder; Michel A Missinou; Pierre-Blaise Matsiegui; Holger Gruss; Rajko Neubauer; Bertrand Lell; John U Que; Gerri B Miller; Peter G Kremsner
Journal:  Clin Infect Dis       Date:  2002-10-25       Impact factor: 9.079

Review 6.  [Hepatitis E: molecular virology, epidemiology and pathogenesis].

Authors:  Francisco Rodríguez-Frias; Rosendo Jardi; María Buti
Journal:  Enferm Infecc Microbiol Clin       Date:  2012-03-03       Impact factor: 1.731

7.  Live oral typhoid vaccine Ty21a induces cross-reactive humoral immune responses against Salmonella enterica serovar Paratyphi A and S. Paratyphi B in humans.

Authors:  Rezwanul Wahid; Raphael Simon; Shah J Zafar; Myron M Levine; Marcelo B Sztein
Journal:  Clin Vaccine Immunol       Date:  2012-04-04

8.  Hepatitis E vaccine development: a 14 year odyssey.

Authors:  Ting Wu; Shao-Wei Li; Jun Zhang; Mun-Hon Ng; Ning-Shao Xia; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2012-06-01       Impact factor: 3.452

9.  Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines.

Authors:  W A Keitel; N L Bond; J M Zahradnik; T A Cramton; J B Robbins
Journal:  Vaccine       Date:  1994       Impact factor: 3.641

10.  Population-based incidence of typhoid fever in an urban informal settlement and a rural area in Kenya: implications for typhoid vaccine use in Africa.

Authors:  Robert F Breiman; Leonard Cosmas; Henry Njuguna; Allan Audi; Beatrice Olack; John B Ochieng; Newton Wamola; Godfrey M Bigogo; George Awiti; Collins W Tabu; Heather Burke; John Williamson; Joseph O Oundo; Eric D Mintz; Daniel R Feikin
Journal:  PLoS One       Date:  2012-01-19       Impact factor: 3.240

View more
  4 in total

1.  Cholera in travelers: shifting tides in epidemiology, management, and prevention.

Authors:  Katie Fillion; Maria D Mileno
Journal:  Curr Infect Dis Rep       Date:  2015-01       Impact factor: 3.725

2.  In vitro characterization and preclinical immunogenicity of Typhax, a typhoid fever protein capsular matrix vaccine candidate.

Authors:  Thomas J Griffin; Ann Thanawastien; Robert T Cartee; John J Mekalanos; Kevin P Killeen
Journal:  Hum Vaccin Immunother       Date:  2019-05-28       Impact factor: 3.452

3.  A disease severity scale for the evaluation of vaccine and other preventive or therapeutic interventions for travellers' diarrhoea.

Authors:  Nicole Maier; Mark S Riddle; Ramiro Gutiérrez; Jamie A Fraser; Patrick Connor; David R Tribble; Chad K Porter
Journal:  J Travel Med       Date:  2022-01-17       Impact factor: 39.194

Review 4.  Travel-Related Typhoid Fever: Narrative Review of the Scientific Literature.

Authors:  Narcisa Muresu; Giovanni Sotgiu; Bianca Maria Are; Andrea Cossu; Clementina Cocuzza; Marianna Martinelli; Sergio Babudieri; Riccardo Are; Marco Dettori; Antonio Azara; Laura Saderi; Andrea Piana
Journal:  Int J Environ Res Public Health       Date:  2020-01-18       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.